Bowman Cox
Executive Editor
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Bowman Cox
COVID-19 Vaccines, Therapies Would Get Billion-Dollar Manufacturing Platform Under House Bill
House coronavirus legislation would boost domestic manufacturing capacity while further scrutinizing global supply chain.
Supply Chain Resilience Measures Included In Senate Coronavirus Bill
Whether major drug shortages result from the COVID-19 pandemic or not, manufacturers would face greater reporting requirements, especially for APIs.
Cipla Plant Gets FDA Warning Letter
Despite the stain on Cipla’s compliance record, the company leads on drug quality in India, with major concerns raised in only 3% of FDA inspections, compared to 11% generally.
API In Ducts And Filters Led To Cipla’s First Drug GMP Warning Letter
Despite the stain on Cipla’s compliance record, the company leads on drug quality in India, with major concerns raised in only 3% of FDA inspections, compared to 11% generally.
Trump Counts On China To Deliver In The Day Of The Coronavirus
President dismisses fears of drug shortages as White House prepares to deliver US from dependence on China’s pharmaceutical manufacturing complex.
China’s Global Pharma Supply Chain Operations Resuming In Wake Of Outbreak, USP Says
USP reference standard sales showed slow resumption of API manufacturing in China and less-than-expected API use in India.